. Author manuscript; available in PMC: 2018 Dec 20.

Published in final edited form as: Curr Protoc Pharmacol. 2017 Dec 20;79:12.16.1–12.16.17. doi: 10.1002/cpph.32

Table 1.

Commonly known ligands of monoamine transporters.

Transporters	DAT		NET		SERT
Endogenous Substrates	dopamine (DA)		norepinephrine (NE), dopamine (DA)		5-hydroxytryptamine (5-HT, serotonin)
Synthetic substrates	amphetamine, methamphetamine, 1-methyl-4-phenylpyridinium (MPP⁺)		amphetamine, methamphetamine, 1-methyl-4-phenylpyridinium (MPP⁺)		MDMA, 1-methyl-4-phenylpyridinium (MPP⁺)
Releasers or efflux promoters	amphetamine, MDMA, phenmetrazine		amphetamine, MDMA, phenmetrazine		amphetamine, MDMA, 1-(3-trifluoromethylphenyl) Piperazine (TPP)
Inhibitors	Compound	Function	Compound	Function	Compound	Function
	Cocaine	Drug of abuse	Nisoxetine	Pharmacological tool	Paroxetine	Therapeutic drug
	Bupropion	Therapeutic drug	Talopram	Pharmacological tool	Sertraline	Therapeutic drug
	GBR12935	Pharmacological tool	Reboxetine	Therapeutic drug	citalopram	Therapeutic drug
	Methylphenidate	Therapeutic drug	Nomifensin	Therapeutic drug	Fluoxetine	Therapeutic drug
	WIN35428	Pharmacological tool	Mazindol	Therapeutic drug	Fluvoxamine	Therapeutic drug
	RTI-55	Pharmacological tool	Amphetamine	Drug of abuse	amitriptyline	Therapeutic drug
	nomifensin	Therapeutic drug	MDMA	Drug of abuse	desipramine	Therapeutic drug
	benztropine	Pharmacological tool	methylphenidate	Therapeutic drug	trimipramine	Therapeutic drug
	JHW 007	Pharmacological tool	Clomipramine	Therapeutic drug	Clomipramine	Therapeutic drug
Commonly used radiolabelled inhibitors	[³H]-GBR12935, [³H]-WIN35428, [³H]-RTI-55		[³H]-mazindol, [³H]-nisoxetine, [³H]-RTI-55		[³H]-paroxetine, [³H]-citalopram, [³H]-RTI-55